PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34704267-3	2022	Recently, the results of a phase I/II study using the antisense oligonucleotides Tofersen to treat familial amyotrophic lateral sclerosis with superoxide dismutase 1 mutation have been reported.	tofersen	81-89	superoxide dismutase 1	Homo sapiens	143-165
32640130-2	2020	Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.	tofersen	30-38	superoxide dismutase 1	Homo sapiens	120-124
32640130-13	2020	CONCLUSIONS: In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.	tofersen	121-129	superoxide dismutase 1	Homo sapiens	39-43
32640130-13	2020	CONCLUSIONS: In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.	tofersen	121-129	superoxide dismutase 1	Homo sapiens	59-63
34704267-4	2022	Intrathecal Tofersen administration resulted in a 36% reduction in superoxide dismutase 1 level in the cerebrospinal fluid.	tofersen	12-20	superoxide dismutase 1	Homo sapiens	67-89
35585374-0	2022	Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.	tofersen	61-69	superoxide dismutase 1	Homo sapiens	109-113
35585374-6	2022	Tofersen is an investigational antisense oligonucleotide designed to reduce synthesis of superoxide dismutase 1 (SOD1) protein through degradation of SOD1 mRNA.	tofersen	0-8	superoxide dismutase 1	Homo sapiens	89-111
35585374-6	2022	Tofersen is an investigational antisense oligonucleotide designed to reduce synthesis of superoxide dismutase 1 (SOD1) protein through degradation of SOD1 mRNA.	tofersen	0-8	superoxide dismutase 1	Homo sapiens	113-117
35585374-6	2022	Tofersen is an investigational antisense oligonucleotide designed to reduce synthesis of superoxide dismutase 1 (SOD1) protein through degradation of SOD1 mRNA.	tofersen	0-8	superoxide dismutase 1	Homo sapiens	150-154
35585374-7	2022	Informed by Pre-fALS and the tofersen clinical development program, the ATLAS study (NCT04856982) is designed to evaluate the impact of initiating tofersen in presymptomatic carriers of SOD1 variants associated with high or complete penetrance and rapid disease progression who also have biomarker evidence of disease activity (elevated plasma NfL).	tofersen	147-155	superoxide dismutase 1	Homo sapiens	186-190
35585374-7	2022	Informed by Pre-fALS and the tofersen clinical development program, the ATLAS study (NCT04856982) is designed to evaluate the impact of initiating tofersen in presymptomatic carriers of SOD1 variants associated with high or complete penetrance and rapid disease progression who also have biomarker evidence of disease activity (elevated plasma NfL).	tofersen	147-155	neurofilament light chain	Homo sapiens	344-347